CCL2 inhibition in mouse models of bladder cancer in situ has been shown to inhibit tumor growth, reduce MDSCs and TPCs, and promote tumor immunosuppression (Liang et al., 2023). This evidence concerns the gene CCL2 and urinary bladder carcinoma.